Stroke is a leading cause of death and disability, affecting over 7 million people in the United States (Towfighi and Saver, 2011; Onwuekwe and EzealaAdikaibe, 2012; Mozaffarian et al., 2015) . Ischemic stroke is caused by the occlusion of a blood vessel in the brain and constitutes the majority of all strokes. It has been widely reported that, at younger ages, men exhibit an increase in stroke incidence compared with women (Reeves et al., 2008) . However, this discrepancy disappears with advancing age, causing stroke incidence in women to become equal if not greater than that in men, depending on the study (Kissela et al., 2004; Rothwell et al., 2005; Lofmark and Hammarstrom, 2007) . Between the ages of 45 and 74 years, women also have significantly lower risk of stroke mortality than men (Reeves et al., 2008) . Similarly to stroke incidence, the mortality benefit for women is lost with older age, and women over the age of 85 years actually have higher stroke mortality than men (Reeves et al., 2008) . Stroke prevalence is about the same for the sexes; however, because there are more females of older age, there are substantially more female stroke survivors than male stroke survivors (Neyer et al., 2007) . In fact, over the age of 85 years, there are two-to SIGNIFICANCE Males and females respond differently to stroke, and those differences are largely the result of cellular and molecular sex hormoneindependent mechanisms. This Mini-Review focuses on sex differences in the immune response and inflammation to mouse models of ischemic stroke. We additionally address how the failure to examine female-specific responses to stroke and test therapies in female stroke models has, in part, contributed to the overall lack of clinical stroke therapeutic success. These findings support the requirement for representation of females in basic stroke therapy research.
threefold more women with stroke, depending on race (Howard et al., 2005) . Women also have poorer stroke outcomes than men and are more likely to suffer from disability, depression, and a lower quality of life (Di Carlo et al., 2003) . The discrepancy in quality of life for women after stroke may be attributed, in part, to older age at stroke onset, poorer baseline health prior to stroke, less social support after stroke, greater chance of being widowed prior to stroke, and a lower chance of receiving stroke therapies at diagnosis (Reeves et al., 2008) .
BASIC STUDIES IN ANIMAL
MODELS OF STROKE There are many methods for mimicking ischemic stroke in rodents. Each model has advantages and disadvantages in terms of its ability to replicate human ischemic events and reproducibility (Casals et al., 2011; Canazza et al., 2014; Fluri et al., 2015) . The permanent or transient middle cerebral artery occlusion (MCAO) model is one of the best-characterized models of ischemic stroke because of its reproducibility and its ability to simulate human stroke closely (Fluri et al., 2015) . Multiple studies using in vivo rodent models of stroke have demonstrated that young females have smaller infarcts than males after ischemic injury (Alkayed et al., 1998; Murphy et al., 2004; Lang and McCullough, 2008; Vagnerova et al., 2008; Cheng and Hurn, 2010; Siegel et al., 2010; Banerjee et al., 2013; Manwani et al., 2013; Dotson et al., 2015) . However, just as in humans, in whom ischemic protection is decreased in postmenopausal women, aging female rodents (14-22 months) no longer display a protective phenotype to experimental stroke and can have even larger infarcts compared with males of the same age (Manwani et al., 2013) . Rodent stroke models can be extremely useful because of their ability to identify and isolate specific ischemic mechanisms. The roles of sex hormones, inflammation, and the immune response to stroke have all been detailed in rodent stroke models, although more so in young male rodents.
SEX HORMONES IN ANIMAL
STROKE MODELS The effect of sex hormones on stroke can be observed in rodent disease models. As discussed above, protection against ischemic brain injury after experimental stroke in young adult female rats disappears after reproductive senescence (Alkayed et al., 2000) . The same study found that ovarian hormones restore ischemic protection in reproductive, senescent female rats, independent of blood flow. Alternatively, blood flow mechanism is indicative of hormone protection in young female rats compared with male or ovariectomized female rats after experimental stroke (Alkayed et al., 1998) . Sex steroids also modulate STAT3, a transcription factor that is activated in neurons after cerebral ischemia in a sex-specific manner, with higher activation in females than in males (Di Domenico et al., 2012) . In humans, however, treatment of stroke in postmenopausal women with exogenous estrogen has failed to show any benefit and has even shown increased risk of stroke compared with placebo treatment (Simon et al., 2001; Viscoli et al., 2001; Hendrix et al., 2006) . Despite the mechanism of sex hormone protection during stroke, the failure of human estrogen replacement clinical trials indicates a cellular and molecular, sex hormoneindependent means of protection.
IMMUNE CELLS HAVE SEX DIFFERENCES
It is increasingly clear that males and females exhibit unique responses to disease and that differences in the immune system contribute greatly to those disparities. Biological sex shapes how our immune cells function in various circumstances and leads to sex-specific outcomes. For example, females initiate an elevated immune response to antigenic challenge compared with males, leading to a more efficient clearance of pathogens yet also promoting a higher incidence of inflammatory and autoimmune diseases (Klein, 2012) . Among the total population diagnosed with an autoimmune disease, almost 80% are female (Libert et al., 2010) . Females exhibit greater toll-like receptor expression (Klein et al., 2010) and an increase in number and function of monocytes, macrophages, and dendritic cells than males (Boissier et al., 2003; Xia et al., 2009; Melgert et al., 2010) . Additionally, antigen-presenting cells from females present peptides better than the same cells from males (Weinstein et al., 1984) . Females also exhibit an overall heightened adaptive immune response that specifically leads to a Th1-skewed response (Villacres et al., 2004) . Sex differences in cellular immune function directly correlate with increases in diseases such as Sj€ ogren's syndrome, Hashimoto's thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, inflammatory bowel disease, allergy, and eczema for females (Okoro and Kane, 2009; Libert et al., 2010; Ziyab et al., 2010; Tam et al., 2011) .
ISCHEMIC DAMAGE AND INFLAMMATION
Brain-specific cellular and molecular responses reflect more inflammatory microglia after experimental stroke in young male mice compared with females (Banerjee et al., 2013; Dotson et al., 2015) . Microglia cultured from young female MCAO mice show a reduced expression of interleukin (IL)-1b and macrophage inflammatory protein-1a compared with male MCAO mice (Bodhankar et al., 2015) . Young male mice also exhibit increased expression of inflammatory genes in the ischemic brain Abbreviations GM-CSF granulocyte macrophage colony stimulating factor LPS lipopolysaccharide MCAO middle cerebral artery occlusion MG microglia MHC major histocompatibility complex Treg regulatory T cell after experimental stroke compared with females, including genes associated with T-cell function, adhesion molecules, cell signaling, major histocompatibility complex (MHC) and costimulatory signals, cell death, and inflammatory cytokines (Dotson et al., 2015) . Distinct changes in miRNAs after ischemic events in male and female brains have been found to influence mechanisms underlying sexually dimorphic responses to stroke in addition to an miRNA signature response to ischemia that is common to both sexes (Lusardi et al., 2014) . Even microvasculature in the brain contributes to sex differences in stroke. Endothelial cells isolated from the microvasculature of female brains are more resistant to ischemic injury compared with endothelial cells in males, which can be attributed to lower expression of soluble epoxide hydrolase and higher levels of vasoprotective epoxyeicosatrienoic acids (Gupta et al., 2012; Davis et al., 2013; Zhang et al., 2013) .
PERIPHERAL IMMUNE RESPONSE TO ISCHEMIC STROKE After ischemic stroke, peripheral leukocytes become activated and can migrate to the site of injury, perpetuating neurological damage (Offner et al., 2006a,b; Seifert et al., 2012a,b) . It has been widely reported that the spleen, specifically, contributes to stroke outcome and, as reported in humans (Sahota et al., 2013) , the spleens of rodents decrease in size after stroke (Offner et al., 2006a,b; Seifert et al., 2012a,b) . Young male rodent stroke models demonstrate that ischemic injury causes the spleen to release inflammatory immune cells into the periphery and that the elimination of the spleen significantly improves stroke outcome (Ajmo et al., 2008; Ostrowski et al., 2012; Pennypacker and Offner, 2014; Dotson et al., 2015) . Splenic atrophy associated with stroke is also accompanied by an increase in circulating macrophages in the blood (Offner et al., 2006b ). The peripheral immune response to stroke is sex specific in both the spleen and the blood. Young male mice have a greater frequency of activated CD4
1 T cells and more VLA-4-expressing cells in the spleen after experimental stroke than female mice (Banerjee et al., 2013) . Moreover, splenectomy prior to MCAO significantly reduces infarct volume and activated microglia in the brain of male but not female mice, indicating that the peripheral immune response is more influential for stroke outcome in males (Dotson et al., 2015 ; Fig. 1 ). Splenectomy before MCAO also significantly reduces circulating macrophages/monocytes and activated T cells in males but not females, resulting in reduction of ischemic damage in males but not females (Dotson et al., 2015) .
REGULATORY FACTORS IN
ISCHEMIC STROKE Factors that regulate the immune response have the potential to be attractive therapeutic targets for stroke. Foxp3 regulatory T cells (Tregs) are critical regulators of inflammatory disease, such as autoimmunity, and are differentially controlled between the sexes. Recent findings indicate that Foxp3 Tregs are regulated by hormonal fluctuations that can disrupt the balance between Tregs and effector immune cells, causing different sex responses to inflammation and autoimmune disease (Nie et al., 2015) . In young male mice, the frequency of CD4 Tregs in the spleen increases after MCAO (Offner et al., 2006b) . However, the data on whether CD4
1 regulatory T cells resolve or intensify stroke-related neuronal tissue damage are conflicting (Schabitz, 2013; Xu et al., 2013) . Some studies have indicated that CD4
1 Tregs can protect against brain tissue damage following stroke and, therefore, improve stroke outcome (Liesz et al., 2009; and Chamorro, 2009; Li et al., 2013) . Other studies have identified Tregs as harmful aggravators of neurodegeneration (Kleinschnitz and Wiendl, 2013; Kleinschnitz et al., 2013) or, alternatively, have indicated that CD4
1 Tregs have no influence on ischemic damage at all Gu et al., 2012; Stubbe et al., 2013) . Additionally, there have been no observable differences in the frequency of splenic or circulating CD4
1 Tregs between young male and female mice after MCAO (Dotson et al., 2015 (Dotson et al., , 2016b 
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1 Tregs are directly correlated with a better initial stroke outcome and are specifically more prevalent in the ischemic tissue of young female mice after MCAO than in males (Banerjee et al., 2013; Bodhankar et al., 2013) . Young female mice also have more circulating CD8 1 Tregs after MCAO than males (Dotson et al., 2015) . However, studies in humans have indicated that an increase in serum IL-10 in females after stroke is associated with poorer acute and long-term outcome and suggest that IL-10 levels may be a result of factors that interact with sex, such as age and stroke severity (Conway et al., 2015) . Fig. 3 . Increased microglial surface expression of IL-10R by female microglia and IL-10 production by male microglia post-MCAO. Primary MG isolated and cultured from MCAO-treated WT male and female mice were harvested after 21 days in vitro (at confluence) and cultured in GM-CSF-free medium for 5 days. MG were stimulated with 10 ng/ml LPS for 4 hr. Supernatants were discarded after 4 hr, and one of the following treatments was given in 1 ml fresh culture medium: no treatment, 20 ng recombinant IL-10 (rIL-10), or IL-10 1 B cells at a 1:1 ratio with MG. The MG cells were incubated with mentioned treatments at 37 8C and 5% CO 2 for 24 hr, and IL-10 receptor (IL-10R) or IL-10 production was determined by flow cytometry. Values are mean 6 SEM. Data are representative of two separate coculture setups, with each treatment condition performed in duplicate for every experimental setup. Statistical differences between the two sexes were determined by two-way ANOVA, followed by post hoc Bonferroni multiple-comparisons test. 
Fig. 2. Treatment with IL-10
1 B cells promotes M2 phenotype induction in microglia post-MCAO. Primary MG, isolated and cultured from MCAO-treated WT male and female mice, were harvested after 21 days in vitro (at confluence) and cultured in GM-CSFfree medium for 5 days. MG were stimulated with 10 ng/ml LPS for 4 hr. Supernatants were discarded after 4 hr, and one of the following treatments was given in 1 ml fresh culture medium: no treatment, 20 ng recombinant IL-10 (rIL-10), 20 ng/ml rIL-4, or IL-10 1 B cells at a 1:1 ratio with MG. The MG cells were incubated with mentioned treatments at 37 8C and 5% CO 2 for 24 hr, and the M2 marker CD0206 was determined by flow cytometry. Values are mean 6 SEM. Data are representative of two separate coculture setups, with each treatment condition performed in duplicate for every experimental setup. Statistical analysis was performed by one-way ANOVA, with post hoc Dunnett test. Statistical differences between the two sexes were determined by two-way ANOVA followed by post hoc Bonferroni multiple-comparisons test. *P 0.05, ***P 0.001, significant differences between sample means compared with the LPS-stimulated condition; Regulatory microglia and macrophages that display an M2 phenotype have recently been implicated in neuroprotection (Chu et al., 2012; Jalal et al., 2012; Wang et al., 2013; Hu et al., 2015) . Ischemic events lead to an increase in promotion of the M1 phenotype of microglia and infiltrating macrophages which, in turn, perpetuate cell death and inflammation (Schilling et al., 2005; Denker et al., 2007; Hu et al., 2012) . Anti-inflammatory cytokines such as IL-10 and IL-4 can promote the M2 phenotype, thereby improving stroke outcome (Xiong et al., 2011; Hu et al., 2012; Perez-de Puig et al., 2013; Cherry et al., 2014) . Exposure to recombinant IL-10 or IL-10-producing regulatory B cells dampens production of inflammatory cytokines in cultured MCAO microglia from both male and female young mice, but the reduction is significantly greater in females (Bodhankar et al., 2015) . Treatment with IL-10-producing B cells also increases the expression of the M2 marker CD206 in microglia from both male and female mice (Fig. 2) while increasing IL-10 receptors on female microglia and IL-10 production by male microglia (Bodhankar et al., 2015;  Fig. 3 ).
IL-4 has potent anti-inflammatory activity and plays a crucial role in stroke outcome. IL-4 differentiates antigen-stimulated na€ ıve T cells into Th2 cells that secrete anti-inflammatory cytokines such as IL-4, IL-10, and IL-13 that, consequently, suppress Th1 inflammatory effector cells (Abbas et al., 1996) . In young male mice, loss of IL-4 signaling results in an increase in infarct volume and inflammation, which is reversed with replacement of exogenous IL-4 (Xiong et al., 2011) . Another study conducted with young male mice suggests that IL-4 is preferentially produced and secreted by neurons after ischemic stroke and leads to an increase of IL-4R on microglia, providing more evidence for IL-4 as an endogenous defense mechanism to stroke (Zhao et al., 2015) . IL-4 has also been shown to be important for neuroprotection of young female mice after stroke. Loss of IL-4 in female mice exacerbated infarct and increased inflammatory cells in the brain, thus eliminating sex difference after experimental stroke (Xiong et al., 2015) . M2 microglia are reduced in the brains of female IL-4 KO mice but not males, supporting the neuroprotective role of IL-4 in females (Xiong et al., 2015) . Additionally, treatment of MCAO microglia cells with regulatory B cells preferentially increases IL-4R expression and IL-4 production by female cells (Bodhankar et al., 2015; Fig. 4) .
TRANSLATION OF THERAPIES TO
BOTH SEXES The difference in how males and females respond to stroke must be a major consideration when designing new stroke therapies. Numerous therapies have exhibited neuroprotection in the laboratory but have failed to translate to clinical success, in part because of the lack of females in basic research (Turner et al., 2013) . One promising target for stroke therapy is peroxisome proliferatoractivated receptor-a (PPARa). PPARa is a nuclear hormone receptor and ligand-activated transcription factor that negatively regulates inflammation via the nuclear factor-jB signaling pathway (Delerive et al., 2001) . PPARa also plays a role in oxidative stress and cell adhesion (Poynter and Daynes, 1998; Marx et al., 1999) . PPARa is widely expressed in the body, but it is of particular interest as a target for stroke therapy because of its expression in brain tissue and in the white pulp of the spleen (Kainu et al., 1994; Braissant et al., 1996; Cullingford et al., 1998; Bishop-Bailey, 2000; Moreno et al., 2004) . PPARa is expressed at the cellular level in macrophages, T cells, and B cells (Chinetti et al., 1998; Jones et al., 2002) .
PPARa agonist treatment has been effective at neuroprotection from stroke in male mice when given prior to stroke onset. PPARa agonist improves stroke outcome by reducing adhesion molecule expression in the brain and, thereby, limiting early neutrophil infiltration, reducing inflammatory factors, regulating oxidative stress, and increasing cerebral blood flow (Deplanque et al., 2003; Collino et al., 2006; Guo et al., 2010; Ouk et al., 2013 Ouk et al., , 2014 Losey et al., 2015) . However, PPARa agonists did 1 B cells leads to increased IL-4R expression and IL-4 production by female microglia post-MCAO. Primary MG, isolated and cultured from MCAO-treated WT male and female mice, were harvested after 21 days in vitro (at confluence) and cultured in GM-CSF-free medium for 5 days. MG were stimulated with 10 ng/ml LPS for 4 hr. Supernatants were discarded after 4 hr, and one of the following treatments was given in 1 ml fresh culture medium: no treatment, 20 ng recombinant IL-4 (rIL-4), or IL-10
1 B cells at a 1:1 ratio with MG. The MG cells were incubated with mentioned treatments at 37 8C and 5% CO 2 for 24 hr and IL-4R expression and IL-4 production were determined by flow cytometry. Values are mean 6 SEM. Data are representative of two separate coculture setups, with each treatment condition performed in duplicate for every experimental setup. Statistical differences between the two sexes were determined by two-way ANOVA, followed by post hoc Bonferroni multiple-comparisons test. not have the same protective effect in female mice subjected to MCAO (Dotson et al., 2016b) . The lack of therapeutic translation to females is likely due to lower expression of PPARa receptors in female tissues and immune cells and, therefore, a lack of immune regulation after stroke, specifically in the periphery (Jalouli et al., 2003; Dunn et al., 2007; Dotson et al., 2015 Dotson et al., , 2016b Dotson et al., , 2016c .
Another potential stroke target is poly(ADP-ribose) polymerase (PARP1). Loss of PARP1 in young male mice led to neuroprotection from stroke (Eliasson et al., 1997; McCullough et al., 2005) . However, young female PARP1 KO mice or WT mice treated with a PARP1 inhibitor had no protection or intensified neurological damage after ischemic injury (Hagberg et al., 2004; McCullough et al., 2005) . Minocycline is a tetracycline derivative used to treat bacterial infections. Minocycline acts as a PARP inhibitor and, therefore, has neuroprotective activity in neurodegenerative disorders (Yrjanheikki et al., 1999; Alano et al., 2006; Lampl et al., 2007) . When both sexes were tested in mouse models of stroke, minocycline was ineffective at reducing ischemic damage in females subjected to the MCAO model (Li and McCullough, 2009 ), but it did improve females' stroke outcome in a thromboembolic model (Hoda et al., 2011) .
Recombinant T-cell receptor ligand (RTL) has been uysed to treat experimental stroke in mice (Burrows et al., 1998 (Burrows et al., , 2001 Vandenbark et al., 2003; Huan et al., 2004; Subramanian et al., 2009; Akiyoshi et al., 2011; Dotson et al., 2014 Dotson et al., , 2016a . RTL molecules consist of the a1 and b1 domains of MHC class II molecules expressed as a single polypeptide with or without antigenic amino terminal extensions (Burrows et al., 1999; Vandenbark et al., 2003) . RTLs are partial agonists that deactivate effector T cells to become nonresponsive (Burrows et al., 2001; Wang et al., 2003) . RTL inhibits binding of macrophage migration inhibitory factor (MIF) to CD74 and blocks downstream inflammatory effects in the CNS by directly binding to and downregulating the cell surface expression of CD74 (MHC class II invariant chain) on CD11b 1 monocytes Vandenbark et al., 2013) . RTL1000 consists of a human leukocyte antigen-antigen D-related (HLA-DR) 2 moiety linked to human myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide and has been shown to resolve infarct in young male and female humanized DR2 mice subjected to MCAO Pan et al., 2014) . HLA-DRa1-MOG-35-55 is a novel recombinant protein consisting of the HLA-DRa1 domain linked to MOG-35-55 peptide but lacking the b1 domain found in RTL (Benedek et al., 2014) . HLADRa1-MOG-35-55 has also been shown to reduce infarct volume significantly after MCAO in young male mice yet requires a tenfold greater concentration to achieve the same result in female mice (Benedek et al., 2014; Pan et al., 2014) . As shown in Figure 5 , sex differences in inflammation that are mediated through MIF/ CD74 interactions or MIF-independent mechanisms are thought to be the reason for this discrepancy (Pan et al., 2014) .
CONCLUSIONS
As the U.S. population ages, the incidence of stroke will likely increase. Stroke prevalence is projected to increase by 3.4 million individuals, and medical costs associated with stroke will triple between the years 2012 and 2030 (Ovbiagele et al., 2013) . This increase will be disproportionate for the eldery female population and will accentuate stroke-related disabilities (Lai et al., 2005; Manwani and McCullough, 2011) . Prior preclinical trials have failed to yield reproducible results or effective new stroke therapies. Thus, standardized guidelines for study design and data reporting in preclinical randomized controlled trials are required for successful translation of promising experimental approaches to effective clinical therapies (Llovera and Liesz, 2016) . Therefore, the inclusion of sex, age, multiple disease models, and comorbidities in the study design of basic research is of utmost importance.
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